We are live on ! Find out more
BSX icon

Boston Scientific

928 hedge funds and large institutions have $60.3B invested in Boston Scientific in 2022 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 329 increasing their positions, 314 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 143 | Existing positions closed: 60

27% more funds holding in top 10

Funds holding in top 10: 2228 (+6)

17% more capital invested

Capital invested by funds: $51.5B → $60.3B (+$8.84B)

7% more funds holding

Funds holding: 864928 (+64)

5% more repeat investments, than reductions

Existing positions increased: 329 | Existing positions reduced: 314

2.05% less ownership

Funds ownership: 93.31%91.27% (-2%)

33% less call options, than puts

Call options by funds: $203M | Put options by funds: $303M

Holders
928
Holders Change
+64
Holders Change %
+7.41%
% of All Funds
14.92%
Holding in Top 10
28
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+27.27%
% of All Funds
0.45%
New
143
Increased
329
Reduced
314
Closed
60
Calls
$203M
Puts
$303M
Net Calls
-$100M
Net Calls Change
-$80.4M
Name Holding Trade Value Shares
Change
Change in
Stake
TAM
926
Tucker Asset Management
Colorado
$185
WIM
927
Westside Investment Management
California
$28
Holocene Advisors
928
Holocene Advisors
New York
-$132M -3,398,887 Closed
Balyasny Asset Management
929
Balyasny Asset Management
Illinois
-$90.9M -2,347,335 Closed
DCP
930
D1 Capital Partners
New York
-$38.7M -1,000,000 Closed
HM
931
HealthCor Management
New York
-$37.1M -958,600 Closed
MCM
932
Moore Capital Management
New York
-$18.6M -479,888 Closed
IHAM
933
Integral Health Asset Management
New York
-$13.6M -350,000 Closed
MA
934
MUFG Americas
New York
-$12.2M -314,202 Closed
GCM
935
Glenview Capital Management
New York
-$6.48M -167,213 Closed
Connor, Clark & Lunn Investment Management (CC&L)
936
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$6.39M -165,073 Closed
SAM
937
Synergy Asset Management
Washington
-$3.6M -92,995 Closed
UOC
938
UBS O'Connor
Illinois
-$2.71M -70,005 Closed
LCM
939
Laurion Capital Management
New York
-$2.52M -64,949 Closed
ACA
940
Aptus Capital Advisors
Alabama
-$2.5M -64,563 Closed
CCS
941
Concentric Capital Strategies
Connecticut
-$2.25M -58,112 Closed
PVI
942
Pura Vida Investments
New York
-$1.88M -48,635 Closed
Acadian Asset Management
943
Acadian Asset Management
Massachusetts
-$1.5M -38,878 Closed
MAM
944
Meeder Asset Management
Ohio
-$977K -25,222 Closed
PI
945
PEAK6 Investments
Illinois
-$953K -22,010 Closed
OPPTF
946
OPSEU Pension Plan Trust Fund
Ontario, Canada
-$824K -20,847 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
947
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$747K -19,300 Closed
FC
948
FORA Capital
Florida
-$727K -18,778 Closed
KA
949
Kintegral Advisory
New York
-$644K -16,618 Closed
E
950
Ergoteles
New York
-$623K -16,077 Closed

BSX Hedge Fund Activity: Q4 2022 in Review

928 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q4 2022, worth a combined $60.3B — up 17% from $51.5B a quarter earlier.

Buyers outnumbered sellers: 143 funds opened new BSX positions and 60 closed out — a net gain of 83 holders — while 329 added to existing stakes and 314 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $825M. The largest seller was Janus Henderson Group, cutting an estimated $1.13B.

  • 928 institutional investors held Boston Scientific (BSX) as of Q4 2022, up from 864 in Q3 2022.
  • Funds reported $60.3B of Boston Scientific stock for Q4 2022, up 17% quarter-over-quarter.
  • 143 funds opened new Boston Scientific positions in Q4 2022 and 60 closed out, a net change of +83 holders.
  • The largest Boston Scientific buyer in Q4 2022 was Fidelity Investments, an estimated $825M added.
  • The largest Boston Scientific seller in Q4 2022 was Janus Henderson Group, an estimated $1.13B sold.

Based on aggregated 13F filings for Q4 2022.